ArticleFrontiers in oncology2021

Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase.

Fausto Castagnetti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.